LumiraDx
LumiraDx Q4 Revenues Fall 65 Percent
The company was impacted by a $96.3 million accounting impairment due to excess manufacturing and inventory related to its COVID-19 test scale-up.
LumiraDx Secures FDA Emergency Use Authorization, UK Approval for COVID-19, Flu Test
The LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete test is a laboratory-use assay run on open RT-PCR instruments.
LumiraDx Receives Notice From Nasdaq Over Missed Listing Requirement
The UK-based point-of-care diagnostics company received the letter because its common shares on the Nasdaq closed below $1 for 30 consecutive trading days.
Top Five Articles on 360Dx Last Week: White House COVID-19 Antigen Testing; LumiraDx; More
Last week, readers were most interested in the White House reopening the nationwide free COVID-19 antigen testing program.
Earnings Roundup: OraSure Technologies, LumiraDx, Opko, More
OraSure, LumiraDx, Opko, and Epigenomics reported their financial results this week.
Jul 19, 2022
LumiraDx to Publicly Offer 40M Shares
May 12, 2022
LumiraDx Q1 Revenues up 18 Percent
Apr 6, 2022
Jan 11, 2022
LumiraDx Gets CE Mark for C-Reactive Protein Test
Oct 27, 2021
BTIG Initiates Coverage of LumiraDx With Buy Rating
Oct 7, 2021